Page 670 - Hematology_ Basic Principles and Practice ( PDFDrive )

570.e2 Part V Red Blood Cells

52. Fang J, Menon M, Kapelle W, et al: EPO modulation of cell-cycle regu- 76. Li H, Rybicki AC, Suzuka SM, et al: Transferrin therapy ameliorates
latory genes, and cell division, in primary bone marrow erythroblasts. disease in beta-thalassemic mice. Nat Med 16:177, 2010.
Blood 110:2361, 2007. 77. Gelderman MP, Baek JH, Yalamanoglu A, et al: Reversal of hemochro-
53. Socolovsky M: Molecular insights into stress erythropoiesis. Curr Opin matosis by apotransferrin in non-transfused and transfused Hbbth3/+
Hematol 14:215, 2007. (heterozygous b1/b2 globin gene deletion) mice. Haematologica
54. Libani IV, Guy EC, Melchiori L, et al: Decreased differentiation of 100:611–622, 2015.
erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. 78. Logothetis J, Loewenson RB, Augoustaki O, et al: Body growth in
Blood 112:875, 2008. Cooley’s anemia (homozygous beta-thalassemia) with a correlative study
55. Melchiori L, Gardenghi S, Rivella S: beta-Thalassemia: HiJAKing inef- as to other aspects of the illness in 138 cases. Pediatrics 50:92, 1972.
fective erythropoiesis and iron overload. Adv Hematol 2010:938640, 79. Baty J, Blackfan K, Diamond L: Blood studies in infants and in chil-
2010. dren. I. Erythroblastsic anemia: a clinical and pathologic study. Am J
56. Wood AD, Chen E, Donaldson IJ, et al: ID1 promotes expansion and Dis Child 43:665, 1932.
survival of primary erythroid cells and is a target of JAK2V617F-STAT5 80. Silvestroni E, Bianco I: Screening for microcytemia in Italy: analysis of
signaling. Blood 114:1820, 2009. data collected in the past 30 years. Am J Hum Genet 27:198, 1975.
57. Rivella S: Ineffective erythropoiesis and thalassemias. Curr Opin 81. Smith CH, Sisson TR, Floyd WH, Jr, et al: Serum iron and iron-
Hematol 16:187, 2009. binding capacity of the serum in children with severe Mediterranean
58. Fibach E, Rachmilewitz E: The role of oxidative stress in hemolytic (Cooley’s) anemia. Pediatrics 5:799, 1950.
anemia. Curr Mol Med 8:609, 2008. 82. Fessas P: Inclusions of hemoglobin erythroblasts and erythrocytes of
59. Marinkovic D, Zhang X, Yalcin S, et al: Foxo3 is required for the thalassemia. Blood 21:21, 1963.
regulation of oxidative stress in erythropoiesis. J Clin Invest 117:2133, 83. Fessas P, Loukopoulos D, Kaltsoya A: Peptide analysis of the inclusions
2007. of erythroid cells in beta-thalassemia. Biochim Biophys Acta 124:430,
60. Kerenyi MA, Grebien F, Gehart H, et al: Stat5 regulates cellular iron 1966.
uptake of erythroid cells via IRP-2 and TfR-1. Blood 112:3878, 2008. 84. Cutillo S, Meloni T: Serum concentrations of haptoglobin and hemo-
61. Zhu BM, McLaughlin SK, Na R, et al: Hematopoietic-specific Stat5- pexin in favism and thalassemia. Acta Haematol 52:65, 1974.
null mice display microcytic hypochromic anemia associated with 85. Arcasoy A, Cavdar AO: Changes of trace minerals (serum iron,
reduced transferrin receptor gene expression. Blood 112:2071, 2008. zinc, copper and magnesium) in thalassemia. Acta Haematol 53:341,
62. Gardenghi S, Grady RW, Rivella S: Anemia, ineffective erythropoiesis, 1975.
and hepcidin: interacting factors in abnormal iron metabolism leading 86. Prasad AS, Diwany M, Gabr M, et al: Biochemical studies in thalas-
to iron overload in beta-thalassemia. Hematol Oncol Clin North Am semia. Ann Intern Med 62:87, 1965.
24:1089, 2010. 87. Wapnick AA, Lynch SR, Krawitz P, et al: Effects of iron overload on
63. Weizer O, Adamsky K, Breda L, et al: Hepcidin expression in cultured ascorbic acid metabolism. Br Med J 3:704, 1968.
liver cells responds differently to iron overloaded sera derived from 88. Wapnick AA, Lynch SR, Charlton RW, et al: The effect of ascorbic
patients with thalassemia and hemochromatosis. Blood 104:3196, acid deficiency on desferrioxamine-induced urinary iron excretion. Br
2004. J Haematol 17:563, 1969.
64. Kautz L, Jung G, Valore EV, et al: Identification of erythroferrone as 89. Jandl JH, Greenberg MS: Bonemarrow failure due to relative nutritional
an erythroid regulator of iron metabolism. Nat Genet 46(7):678–684, deficiency in Cooley’s hemolytic anemia: painful erythropoietic crises in
2014. doi: 10.1038/ng.2996. [Epub 2014 Jun 1]. response to folic acid. N Engl J Med 260:461, 1959.
65. Tanno T, Porayette P, Sripichai O, et al: Identification of TWSG1 as a 90. Luhby AL, Cooperman JM: Folic-acid deficiency in thalassaemia major.
second novel erythroid regulator of hepcidin expression in murine and Lancet 2:490, 1961.
human cells. Blood 114:181, 2009. 91. Hyman CB, Landing B, Alfin-Slater R, et al: Dl-alpha-tocopherol, iron,
66. Vilmos P, Gaudenz K, Hegedus Z, et al: The twisted gastrulation family and lipofuscin in thalassemia. Ann N Y Acad Sci 232:211, 1974.
of proteins, together with the IGFBP and CCN families, comprise the 92. Rachmilewitz EA, Shohet SB, Lubin BH: Lipid membrane peroxida-
TIC superfamily of cysteine rich secreted factors. Mol Pathol 54:317, tion in beta-thalassemia major. Blood 47:495, 1976.
2001. 93. Miniero R, Piga A, Luzzatto L, et al: Vitamin E and beta-thalassaemia.
67. Tamary H, Shalev H, Perez-Avraham G, et al: Elevated growth dif- Haematologica 68:562, 1983.
ferentiation factor 15 expression in patients with congenital dyseryth- 94. Hilgartner MW, Smith CH: Coagulation studies as a measure of liver
ropoietic anemia type I. Blood 112:5241, 2008. function in Cooley’s anemia. Ann N Y Acad Sci 119:631, 1964.
68. Ramirez JM, Schaad O, Durual S, et al: Growth differentiation factor 95. Stuart MJ: Platelet dysfunction in homozygous beta-thalassemia.
15 production is necessary for normal erythroid differentiation and is Pediatr Res 13:1345, 1979.
increased in refractory anaemia with ring-sideroblasts. Br J Haematol 96. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment
144:251, 2009. of thalassemia. Blood 89:739, 1997.
69. Casanovas G, Swinkels DW, Altamura S, et al: Growth differentiation 97. Olivieri NF: The beta-thalassemias. N Engl J Med 341:99, 1999.
factor 15 in patients with congenital dyserythropoietic anaemia (CDA) 98. Wonke B: Clinical management of beta-thalassemia major. Semin
type II. J Mol Med 89:811–816, 2011. Hematol 38:350, 2001.
70. Ramos P, Melchiori L, Gardenghi S, et al: Iron metabolism and inef- 99. Porter JB: Practical management of iron overload. Br J Haematol
fective erythropoiesis in beta-thalassemia mouse models. Ann N Y Acad 115:239, 2001.
Sci 1202:24, 2010. 100. Rund D, Rachmilewitz E: Beta-thalassemia. N Engl J Med 353:1135,
71. Rivella S, Nemeth E, Miller JL: Crosstalk between erythropoiesis and 2005.
iron metabolism. Adv Hematol 2010, 2010. 101. Boulad F: Hematopoietic stem cell transplantation for the treatment
72. Dussiot M, Maciel TT, Fricot A, et al: An activin receptor IIA ligand of beta thalassemia. In Kline R, editor: Pediatric hematopoietic stem cell
trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med transplantation, New York, 2006, Informa Healthcare, p 383.
20:398–407, 2014. 102. Wolman IJ: Transfusion therapy in Cooley’s anemia: growth and health
73. Gardenghi S, Ramos P, Marongiu MF, et al: Hepcidin as a therapeutic as related to long-range hemoglobin levels. a progress report. Ann N Y
tool to limit iron overload and improve anemia in beta-thalassemic Acad Sci 119:736, 1964.
mice. J Clin Invest 120:4466, 2010. 103. Ehlers KH, Giardina PJ, Lesser ML, et al: Prolonged survival in patients
74. Tanno T, Bhanu NV, Oneal PA, et al: High levels of GDF15 in thalas- with beta-thalassemia major treated with deferoxamine. J Pediatr
semia suppress expression of the iron regulatory protein hepcidin. Nat 118:540, 1991.
Med 13:1096, 2007. 104. Giardina PJ, Grady RW, Ehlers KH, et al: Current therapy of Cooley’s
75. Kearney SL, Nemeth E, Neufeld EJ, et al: Urinary hepcidin in congeni- anemia. A decade of experience with subcutaneous desferrioxamine.
tal chronic anemias. Pediatr Blood Cancer 48:57, 2007. Ann N Y Acad Sci 612:275, 1990.